2 No-Brainer Stocks to Buy With Less Than $30

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a top corporation that's likely to perform well in the long run. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.Which stocks trading for less than $30 per share are worth investing in today? Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).After hitting about $60 per share in late 2021, Pfizer's stock price has been in free fall, currently standing at just under $22. The pharmaceutical giant is no longer generating tens of billions of dollars in sales from its COVID-19 portfolio. It will soon face important patent cliffs, including that of Eliquis, a blood thinner. And though Pfizer has developed and launched some brand-new products in recent years, none looks quite promising enough for the company to get back in the good graces of investors.Continue reading

Apr 24, 2025 - 11:54

2 No-Brainer Stocks to Buy With Less Than $30

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a top corporation that's likely to perform well in the long run. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.

Which stocks trading for less than $30 per share are worth investing in today? Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).

After hitting about $60 per share in late 2021, Pfizer's stock price has been in free fall, currently standing at just under $22. The pharmaceutical giant is no longer generating tens of billions of dollars in sales from its COVID-19 portfolio. It will soon face important patent cliffs, including that of Eliquis, a blood thinner. And though Pfizer has developed and launched some brand-new products in recent years, none looks quite promising enough for the company to get back in the good graces of investors.